BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025
BioAtla (Nasdaq: BCAB), a clinical-stage biotechnology company specializing in Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, has scheduled its Q2 2025 earnings conference call for August 7, 2025, at 4:30 p.m. ET.
The company will discuss financial results for the quarter ended June 30, 2025, and provide business updates. The earnings release will be available on the company's website before the call. Investors can access the call through the provided domestic and international dial-in numbers or via webcast.
BioAtla (Nasdaq: BCAB), un'azienda biotecnologica in fase clinica specializzata in terapie con anticorpi Conditionally Active Biologic (CAB) per il trattamento dei tumori solidi, ha programmato la sua conference call sui risultati del secondo trimestre 2025 per il 7 agosto 2025 alle 16:30 ET.
L'azienda discuterà i risultati finanziari del trimestre conclusosi il 30 giugno 2025 e fornirà aggiornamenti sulle attività. Il comunicato sui risultati sarà disponibile sul sito web aziendale prima della chiamata. Gli investitori potranno partecipare alla chiamata tramite i numeri di accesso nazionali e internazionali forniti o tramite webcast.
BioAtla (Nasdaq: BCAB), una compañía biotecnológica en etapa clínica especializada en terapias con anticuerpos Conditionally Active Biologic (CAB) para el tratamiento de tumores sólidos, ha programado su conferencia telefónica de resultados del segundo trimestre de 2025 para el 7 de agosto de 2025 a las 4:30 p.m. ET.
La empresa discutirá los resultados financieros del trimestre finalizado el 30 de junio de 2025 y proporcionará actualizaciones comerciales. El comunicado de resultados estará disponible en el sitio web de la compañía antes de la llamada. Los inversores podrán acceder a la llamada mediante los números de teléfono nacionales e internacionales proporcionados o a través de una transmisión web.
BioAtla (나스닥: BCAB)는 고형암 치료를 위한 조건부 활성 생물학적(CAB) 항체 치료제에 특화된 임상 단계 생명공학 회사로, 2025년 8월 7일 오후 4시 30분(동부시간)에 2025년 2분기 실적 컨퍼런스 콜을 예정하고 있습니다.
회사는 2025년 6월 30일 종료된 분기의 재무 결과를 논의하고 사업 현황을 업데이트할 예정입니다. 실적 발표 자료는 콜 전에 회사 웹사이트에서 확인할 수 있습니다. 투자자들은 제공된 국내외 전화번호를 통해 또는 웹캐스트를 통해 콜에 참여할 수 있습니다.
BioAtla (Nasdaq : BCAB), une société de biotechnologie en phase clinique spécialisée dans les anticorps thérapeutiques Conditionally Active Biologic (CAB) pour le traitement des tumeurs solides, a programmé sa conférence téléphonique sur les résultats du deuxième trimestre 2025 le 7 août 2025 à 16h30 ET.
La société discutera des résultats financiers pour le trimestre clos le 30 juin 2025 et fournira des mises à jour commerciales. Le communiqué des résultats sera disponible sur le site web de la société avant l'appel. Les investisseurs pourront accéder à la conférence via les numéros d'appel nationaux et internationaux fournis ou par webcast.
BioAtla (Nasdaq: BCAB), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf Conditionally Active Biologic (CAB)-Antikörpertherapien zur Behandlung solider Tumoren spezialisiert hat, hat seine Telefonkonferenz zu den Ergebnissen des zweiten Quartals 2025 für den 7. August 2025 um 16:30 Uhr ET angesetzt.
Das Unternehmen wird die Finanzergebnisse für das am 30. Juni 2025 beendete Quartal besprechen und Geschäftsinformationen bereitstellen. Die Ergebnisveröffentlichung wird vor der Telefonkonferenz auf der Unternehmenswebseite verfügbar sein. Investoren können über die bereitgestellten nationalen und internationalen Einwahlnummern oder per Webcast teilnehmen.
- None.
- None.
SAN DIEGO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, August 7, 2025 at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2025 and provide business highlights.
Conference Call and Webcast Information
Date: Thursday, August 7, 2025
Time: 4:30 p.m. ET
Webcast Link: BioAtla Second Quarter 2025 Earnings Conference Call
Dial-in Numbers: (800) 274-8461 (domestic), (203) 518-9814 (international)
Conference ID: BIOATLA
The press release with the financial results will be accessible prior to the conference call through “News Releases” in the News & Events section of the company’s website. A replay of the call will also be available through “Events & Presentations” in the Investors section of the company’s website.
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB platform technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. The Company also has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. To learn more about BioAtla, Inc. visit www.bioatla.com.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
FAQ
When is BioAtla (BCAB) reporting Q2 2025 earnings?
How can investors access BioAtla's Q2 2025 earnings call?
What will BioAtla discuss in their Q2 2025 earnings call?
Where can investors find BioAtla's Q2 2025 earnings press release?
